BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

14067

524212

WANBURY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Wanbury performance

Today’s low

Today’s high

₹ 303.00 ₹ 320.95
₹ 313.00

52 week low

52 week high

₹ 152.81 ₹ 329.70
₹ 313.00

Open Price

₹ 313.00

Prev. Close

₹ 312.20

Volume (Shares)

37981.00

Total traded value

₹ 118.88

Upper Circuit

₹ 327.80

Lower Circuit

₹ 296.60

info

Wanbury Share Price Update

As of the latest trading session, Wanbury share price is currently at ₹ 312.2, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 303.00 and ₹ 320.95. Over the past year, Wanbury has achieved a return of 98.37 %. In the last month alone, the return has been 16.30 %. Read More...

Wanbury fundamentals


  • Market cap (Cr)

    1,015.90

  • P/E Ratio (TTM)

    33.71

  • Beta

    1.55

  • Book Value / share

    18.08

  • Return on equity

    38.26%

  • EPS (TTM)

    9.32

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    20.26

info icon alternate text
  • Market cap (Cr)

    1,025.70

  • P/E Ratio (TTM)

    33.71

  • Beta

    1.42

  • Book Value / share

    18.08

  • Return on equity

    38.26%

  • EPS (TTM)

    9.32

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    20.26

info icon alternate text

Wanbury Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 172.00
Operating Expense 154.79
Net Profit 20.26
Net Profit Margin (%) 11.77
Earnings Per Share (EPS) 6.18
EBITDA 31.46
Effective Tax Rate (%) -6.29
Particulars DEC 2024 (Values in Cr)
Revenue 133.45
Operating Expense 133.00
Net Profit 1.22
Net Profit Margin (%) 0.91
Earnings Per Share (EPS) 0.38
EBITDA 14.78
Effective Tax Rate (%) 5.42
Particulars SEP 2024 (Values in Cr)
Revenue 161.19
Operating Expense 154.66
Net Profit 8.02
Net Profit Margin (%) 4.97
Earnings Per Share (EPS) 2.44
EBITDA 21.64
Effective Tax Rate (%) 1.83
Particulars JUN 2024 (Values in Cr)
Revenue 131.11
Operating Expense 131.01
Net Profit 1.04
Net Profit Margin (%) 0.79
Earnings Per Share (EPS) 0.32
EBITDA 11.91
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 139.41
Operating Expense 131.98
Net Profit 8.08
Net Profit Margin (%) 5.79
Earnings Per Share (EPS) 2.47
EBITDA 19.09
Effective Tax Rate (%) 3.23
Particulars MAR 2025 (Values in Cr)
Revenue 599.51
Operating Expense 573.46
Net Profit 30.53
Net Profit Margin (%) 5.09
Earnings Per Share (EPS) 9.32
EBITDA 79.81
Effective Tax Rate (%) -3.31
Particulars MAR 2024 (Values in Cr)
Revenue 575.65
Operating Expense 547.85
Net Profit 30.40
Net Profit Margin (%) 5.28
Earnings Per Share (EPS) 9.29
EBITDA 72.99
Effective Tax Rate (%) 1.23
Particulars MAR 2023 (Values in Cr)
Revenue 499.65
Operating Expense 510.25
Net Profit -10.40
Net Profit Margin (%) -2.08
Earnings Per Share (EPS) -3.18
EBITDA 23.48
Effective Tax Rate (%) -1.06
Particulars MAR 2022 (Values in Cr)
Revenue 511.19
Operating Expense 507.93
Net Profit 81.47
Net Profit Margin (%) 15.93
Earnings Per Share (EPS) 25.29
EBITDA 113.19
Effective Tax Rate (%) -0.43
Particulars MAR 2021 (Values in Cr)
Revenue 392.52
Operating Expense 407.32
Net Profit -12.61
Net Profit Margin (%) -3.21
Earnings Per Share (EPS) -5.04
EBITDA 20.41
Effective Tax Rate (%) -1.61
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.70
ROE % 49.77
ROCE % 33.46
Total Debt to Total Equity 0.00
EBITDA Margin 13.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share -10.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.43
Particulars MAR 2022 (Values in Cr)
Book Value / Share -7.27
ROE % 306.03
ROCE % 16.14
Total Debt to Total Equity 0.00
EBITDA Margin 7.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share -62.46
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.20
Particulars MAR 2020 (Values in Cr)
Book Value / Share -57.39
ROE % 36.16
ROCE % 7.96
Total Debt to Total Equity 0.00
EBITDA Margin 6.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.70
ROE % 38.26
ROCE % 32.14
Total Debt to Total Equity 8.98
EBITDA Margin 12.68
Particulars MAR 2023 (Values in Cr)
Book Value / Share -2.26
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 4.70
Particulars MAR 2022 (Values in Cr)
Book Value / Share 0.57
ROE % 37.03
ROCE % 17.45
Total Debt to Total Equity 0.00
EBITDA Margin 7.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share -52.23
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 5.20
Particulars MAR 2020 (Values in Cr)
Book Value / Share -47.14
ROE % 48.96
ROCE % 8.54
Total Debt to Total Equity 0.00
EBITDA Margin 6.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.89
Total Assets 343.49
Total Liabilities 343.49
Total Equity 27.94
Share Outstanding 32745498
Price to Book Ratio 21.77
Return on Assets (%) 16.29
Return on Capital (%) 40.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.93
Total Assets 303.52
Total Liabilities 303.52
Total Equity -32.81
Share Outstanding 32705498
Price to Book Ratio -16.51
Return on Assets (%) -3.42
Return on Capital (%) -33.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.31
Total Assets 352.54
Total Liabilities 352.54
Total Equity -23.41
Share Outstanding 32665498
Price to Book Ratio 149.12
Return on Assets (%) 23.10
Return on Capital (%) 186.85
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.70
Total Assets 289.17
Total Liabilities 289.17
Total Equity -156.24
Share Outstanding 25015117
Price to Book Ratio -1.59
Return on Assets (%) -4.35
Return on Capital (%) -301.65
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 16.69
Total Assets 278.69
Total Liabilities 278.69
Total Equity -143.45
Share Outstanding 24995117
Price to Book Ratio -0.39
Return on Assets (%) 23.13
Return on Capital (%) -339.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.89
Total Assets 343.49
Total Liabilities 343.49
Total Equity 27.94
Share Outstanding 32745498
Price to Book Ratio 21.77
Return on Assets (%) 8.85
Return on Capital (%) 22.05
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.89
Total Assets 301.89
Total Liabilities 301.89
Total Equity -7.25
Share Outstanding 32705498
Price to Book Ratio -16.51
Return on Assets (%) -3.44
Return on Capital (%) -18.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.27
Total Assets 351.00
Total Liabilities 351.00
Total Equity 2.18
Share Outstanding 32665498
Price to Book Ratio 149.12
Return on Assets (%) 23.21
Return on Capital (%) 117.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.66
Total Assets 287.60
Total Liabilities 287.60
Total Equity -130.65
Share Outstanding 25015117
Price to Book Ratio -1.59
Return on Assets (%) -4.38
Return on Capital (%) -42.35
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 16.65
Total Assets 277.16
Total Liabilities 277.16
Total Equity -117.83
Share Outstanding 24995117
Price to Book Ratio -0.39
Return on Assets (%) 23.25
Return on Capital (%) 971.77
Particulars MAR 2024 (Values in Cr)
Net Income 56.33
Cash from Operations 4.16
Cash from Investing -16.62
Cash from Financing 14.55
Net change in Cash 1.90
Free Cash Flow 21.58
Particulars MAR 2023 (Values in Cr)
Net Income -10.28
Cash from Operations 19.97
Cash from Investing -8.83
Cash from Financing -31.99
Net change in Cash -21.03
Free Cash Flow 32.59
Particulars MAR 2022 (Values in Cr)
Net Income 81.12
Cash from Operations 40.68
Cash from Investing 0.58
Cash from Financing -28.58
Net change in Cash 12.52
Free Cash Flow 50.34
Particulars MAR 2021 (Values in Cr)
Net Income -12.40
Cash from Operations 17.81
Cash from Investing 8.04
Cash from Financing -17.38
Net change in Cash 7.34
Free Cash Flow 22.24
Particulars MAR 2020 (Values in Cr)
Net Income 64.67
Cash from Operations 44.16
Cash from Investing 63.66
Cash from Financing -107.87
Net change in Cash -0.07
Free Cash Flow 51.99
Particulars MAR 2024 (Values in Cr)
Net Income 30.78
Cash from Operations 4.19
Cash from Investing -16.62
Cash from Financing 14.55
Net change in Cash 1.94
Free Cash Flow 21.62
Particulars MAR 2023 (Values in Cr)
Net Income -10.28
Cash from Operations 19.97
Cash from Investing -8.83
Cash from Financing -31.99
Net change in Cash -21.03
Free Cash Flow 32.59
Particulars MAR 2022 (Values in Cr)
Net Income 81.12
Cash from Operations 40.68
Cash from Investing 0.58
Cash from Financing -28.58
Net change in Cash 12.52
Free Cash Flow 50.34
Particulars MAR 2021 (Values in Cr)
Net Income -12.40
Cash from Operations 17.81
Cash from Investing 8.04
Cash from Financing -17.38
Net change in Cash 7.34
Free Cash Flow 22.24
Particulars MAR 2020 (Values in Cr)
Net Income 64.67
Cash from Operations 44.15
Cash from Investing 63.66
Cash from Financing -107.87
Net change in Cash -0.08
Free Cash Flow 51.98
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

Wanbury Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
310.00 -0.70 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 301.70
  • 26 Days 286.70
  • 10 Days 297.80
  • 50 Days 273.10
  • 12 Days 296.40
  • 100 Days 258.30
  • 20 Days 290.80
  • 200 Days 238.80
299.63 PIVOT

First Support

295.57

First Resistance

304.67

Second Support

290.53

Second Resistance

308.73

Third Support

286.47

Third Resistance

313.77

RSI

66.34

ADX

45.38

MACD

9.73

Williams % R

-7.01

Commodity Channel Index (CCI)

141.33

Date

2025-05-20

Week

251008.00

Same Day

113882.00

Month

118799.00

1 Year

1.56

3 Year

0.88

Over 1 Month

16.30%

down

Over 1 Year

98.37%

down

Over 3 Months

48.36%

down

Over 3 Years

71.07%

down

Over 6 Months

6.38%

down

Over 5 Years

74.04%

down

Wanbury shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
58.68%
Promoter Holdings
39.76%
FII
1.55%
DII
0.0%
Promoter Shares(Pledge Percentage)
76.74%
Name Shares Category
Expert Chemicals (india) Pvt Ltd 1.0005561E7 (30.53%) Shareholding of Promoter and Promoter Group
Kingsbury Investments Inc. 3024000.0 (9.23%) Shareholding of Promoter and Promoter Group
Suresh Bhatia 1171651.0 (3.58%) Public Shareholding
Authum Investment And Infrastructure Limited 789956.0 (2.41%) Public Shareholding
Magnum Equifin Private Limited 500100.0 (1.53%) Public Shareholding
East Eight Six Advisors Llp 452538.0 (1.38%) Public Shareholding
Resonance Opportunities Fund 400000.0 (1.22%) Public Shareholding
Milan Manharkant Ganatra 343915.0 (1.05%) Public Shareholding

News

Left Arrow
Right Arrow

Wanbury corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2010 1.0 Final 02 Aug 2010 Equity shares
12 Mar 2009 0.5 Final 16 Mar 2009 Equity shares
13 Sep 2007 2.0 Final 17 Sep 2007 Equity shares
20 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
28 Jul 2005 0.0 Final 01 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Wanbury share result highlights

The Wanbury share price has experienced fluctuations following the company’s recent financial results. Wanbury reported moderate revenue growth, driven by strong demand in the pharmaceutical sector. However, profit margins were impacted by rising input costs and operational expenses. The company’s focus on expanding its product portfolio and enhancing its manufacturing capabilities contributed positively to overall revenue. Despite these efforts, net profit remained under pressure, reflecting the challenges faced in maintaining profitability. Nevertheless, Wanbury’s strategic initiatives in research and development have positioned it for future growth, keeping the Wanbury share price stable, with cautious optimism from investors about the company’s long-term performance.

Wanbury share annual reports

Wanbury’s annual reports provide a comprehensive overview of the company’s financial performance, which directly impacts the Wanbury share price. The reports highlight key metrics such as revenue growth, operational efficiency, and cost management. They also outline the company’s strategic initiatives, including investments in research and development, which are essential for future growth. Investors use these reports to assess Wanbury’s financial stability and long-term potential. The annual reports are crucial for understanding the company’s progress and the factors that drive the Wanbury share price, offering valuable insights into its operational and financial outlook.

Wanbury share dividend

Wanbury has not been a regular dividend-paying company in recent years due to its focus on reinvesting profits into business expansion and research initiatives. The company’s primary goal has been to strengthen its financial position and improve operational efficiencies. As a result, dividend payments have been limited, which may not attract income-focused investors. However, as Wanbury continues to stabilise its financial performance, future dividend payouts may become a possibility. This strategic reinvestment has helped support the long-term stability of the Wanbury share price.

Wanbury Share Price

Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988. The Company is engaged in the business of pharmaceutical and related activities, including research.

The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.

In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007. Pursuant to the aforesaid Order of the Hon'ble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008. Similarly, the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1, 2006. In terms of the said Scheme of Merger, the Company had issued 5,62,618 Equity Shares of face value of Rs. 10/- each to the Equity Shareholders of PPIL on 27 June, 2007, which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively.

The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.

The novel product 'Cdense Gems' was launched in May, 2008. The Company completed the restructuring of the Formulation Division during the year 2013. It launched, Myotol-F, targeted at female infertility in 2013, it launched Folinine. The Company's newly launched products Myotol-F (to treat polycystic ovarian syndrome) and Cal-K2 (in prevention and management of Osteoporosis) were labelled as one of the best launches in 2014.

Parent organization PPI
NSE symbol WANBURY
Founded 1988
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Wanbury Ltd?

Answer Field

The share price of Wanbury Ltd for NSE is ₹ 312.20 and for BSE is ₹ 316.00.

What is the Market Cap of Wanbury Ltd?

Answer Field

The market cap of Wanbury Ltd for NSE is ₹ 1,022.31 Cr. and for BSE is ₹ 1,034.75 Cr. as of now.

What is the 52 Week High and Low of Wanbury Ltd?

Answer Field

The 52 Week High and Low of Wanbury Ltd for NSE is ₹ 329.70 and ₹ 152.81 and for BSE is ₹ 330.00 and ₹ 151.10.

How to Buy Wanbury Ltd share?

Answer Field

You can trade in Wanbury Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Wanbury Ltd?

Answer Field

The 1 year returns on the stock has been 98.37%.

What is the Current Share Price of Wanbury Ltd?

Answer Field

Wanbury Ltd share price is for NSE ₹ 312.20 & for BSE ₹ 316.00 as on Jun 16 2025 01:22 PM.

What is the Market Cap of Wanbury Ltd Share?

Answer Field

The market cap of Wanbury Ltd for NSE ₹ 1,022.31 & for BSE ₹ 1,034.75 as on Jun 16 2025 01:22 PM.

What is the P/E Ratio of Wanbury Ltd Share?

Answer Field

As on Jun 16 2025 01:22 PM the price-to-earnings (PE) ratio for Wanbury Ltd share is 33.71.

What is the PB ratio of Wanbury Ltd Share?

Answer Field

As on Jun 16 2025 01:22 PM, the price-to-book (PB) ratio for Wanbury Ltd share is 18.08.

How to Buy Wanbury Ltd Share?

Answer Field

You can trade in Wanbury Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Wanbury Ltd Share on Bajaj Broking App?

Answer Field

To buy Wanbury Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Wanbury Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Wanbury?

Answer Field

As of the latest available information, the CEO of Wanbury is Mr. Arvind Doshi. He is responsible for overseeing the company’s strategic direction and overall operations, which directly impact the Wanbury share price. His focus on expanding Wanbury’s product offerings and strengthening its position in the pharmaceutical sector plays a key role in driving the company’s financial performance and long-term growth.

When was Wanbury established?

Answer Field

Wanbury was established in 1990. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry, specialising in active pharmaceutical ingredients and formulations. Over the years, Wanbury has expanded its operations, contributing to its strong market presence. This long-standing history has had a positive impact on the Wanbury share price, reflecting the company’s stability and growth potential.

What factors influence the Wanbury share price?

Answer Field

Several factors influence the Wanbury share price, including the company’s financial performance, revenue growth, and profitability margins. External factors such as regulatory changes, demand for pharmaceutical products, and market competition also play a significant role. Additionally, investor sentiment regarding Wanbury’s ability to manage costs, expand its product portfolio, and maintain profitability affects the share price movement.

Is Wanbury debt free?

Answer Field

Wanbury is not entirely debt-free, but it maintains a manageable level of debt. The company’s focus on effective debt management ensures that its financial obligations do not negatively impact its profitability. This controlled debt structure contributes to the overall stability of the Wanbury share price, as investors generally prefer companies with a balanced approach to managing liabilities and sustaining long-term growth.

How has the Wanbury share price performed over the past year?

Answer Field

Over the past year, the Wanbury share price has experienced moderate fluctuations, reflecting the company’s financial performance and market conditions. While the company has seen revenue growth, challenges related to rising input costs and operational expenses have impacted profitability. Despite these hurdles, the Wanbury share price has remained relatively stable, with investors maintaining cautious optimism about the company’s future growth potential.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|